For many years hematologists have used the microscope to identifya complete remission of leukemia after treatment with chemotherapy.In a hematologic complete remission, we know that a large portionof the leukemic cells remain out of sight. These cells, invisibleto the microscopist, are the components of an important clinicalproblem termed "minimal residual disease."
The concept of minimal residual disease and its detection anderadication were the topic of a special series of conferencesheld in Rotterdam, the Netherlands, in 1983 and subsequent years.In those days, we were beginning to see a substantial numberof patients with . . . [Full Text of this Article]
Source Information
From Erasmus University Medical Center, Rotterdam, the Netherlands.
This article has been cited by other articles:
Quintas-Cardama, A., Cortes, J.
(2008). Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia. Clin. Cancer Res.
14: 4392-4399
[Abstract][Full Text]
Kawano, T., Ito, M., Raina, D., Wu, Z., Rosenblatt, J., Avigan, D., Stone, R., Kufe, D.
(2007). MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells. Cancer Res.
67: 11576-11584
[Abstract][Full Text]
Kometani, K., Aoki, M., Kawamata, S., Shinozuka, Y., Era, T., Taniwaki, M., Hattori, M., Minato, N.
(2006). Role of SPA-1 in Phenotypes of Chronic Myelogenous Leukemia Induced by BCR-ABL-Expressing Hematopoietic Progenitors in a Mouse Model.. Cancer Res.
66: 9967-9976
[Abstract][Full Text]
